News & Updates

In the ENSEMBLE PLUS study, there appears to be no difference in terms of the frequency and severity of infusion-related reactions (IRRs) between the conventional and shorter infusions of ocrelizumab for the treatment of early relapsing-remitting multiple sclerosis (RRMS). However, patients gravitated towards the shorter regimen more than the conventional method.

The dengue vaccine confers substantial protective benefit on children aged 10 to 15 years, reports a study in the Philippines, which was presented at the recent ESPID 2023.

Low-dose drug combinations that incorporate between three and four blood pressure (BP)-lowering medications appear to be well tolerated and effective for the initial or early management of hypertension, according to the results of a systematic review and meta-analysis.

The use of rivaroxaban in nonhospitalized patients with symptomatic COVID-19 falls short of reducing the composite endpoint of venous and arterial thrombotic events, hospitalization, and death, according to data from PREVENT-HD*.

P2B001, an investigational drug formulation that combines extended release (ER) doses of pramipexole and rasagiline, shows promise in managing Parkinson’s Disease (PD), conferring symptom control similar to that achieved with the marketed ER pramipexole while reducing the troublesome side effect of excessive daytime sleepiness.